New anemia pill challenges standard shot for dialysis patients

NCT ID NCT03439137

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called MT-6548 against a standard treatment (darbepoetin alfa) for anemia in people on dialysis for chronic kidney disease. About 323 participants in Japan received either the new drug or the standard one to see if it worked as well at keeping hemoglobin levels stable. The goal was to find a safe and effective alternative for managing anemia in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia anemia due to chronic disorder chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA; HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

Research site

Aichi, Japan
Research site

Chiba, Japan
Research site

Fukui, Japan
Research site

Fukuoka, Japan
Research site

Fukushima, Japan
Research site

Gunma, Japan
Research site

Hiroshima, Japan
Research site

Hokkaido, Japan
Research site

Hyōgo, Japan
Research site

Ibaraki, Japan
Research site

Kagawa, Japan
Research site

Kagoshima, Japan
Research site

Kanagawa, Japan
Research site

Kumamoto, Japan
Research site

Kyoto, Japan
Research site

Miyagi, Japan
Research site

Nagano, Japan
Research site

Nagasaki, Japan
Research site

Okayama, Japan
Research site

Okinawa, Japan
Research site

Osaka, Japan
Research site

Ōita, Japan
Research site

Saitama, Japan
Research site

Shiga, Japan
Research site

Shizuoka, Japan
Research site

Tokushma, Japan
Research site

Tokyo, Japan
Research site

Yamagata, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.